Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.
Acts as a beta-emitting radionuclide which binds to somatostatin receptors, particularly subtype 2 receptors. Once bound to these receptors, the compound is internalized and then emits beta radiation which leads to cellular damage in somatostatin receptor-positive cells and in surrounding cells.
Improvement in progression-free survival.
Absorption: IV administration results in complete bioavailability.
Distribution: Extensively distributed to extravascular tissues.
Metabolism and Excretion: Does not undergo hepatic metabolism. Primarily excreted in urine.
Half-life: 71 hr.
TIME/ACTION PROFILE (blood concentrations)
end of infusion
Up to 30 days
OB: Pregnancy (may cause fetal harm);
Use Cautiously in:
Severe hepatic impairment
Hepatic metastases (↑ risk of hepatotoxicity)
Rep: Women of reproductive potential and men with female partners of reproductive potential;
Pedi: Safety and effectiveness not established in children.
* CAPITALS indicate life-threatening. Underline indicate most frequent.
Effectiveness may be ↓ by somatostatin analogs, including octreotide ; discontinue long-acting somatostatin analogs ≥4 wk and short-acting somatostatin analogs ≥24 hr before each dose.
Effectiveness may be ↓ by corticosteroids ; avoid repeated administration of high-dose corticosteroids during treatment.
IV (Adults): 7.4 GBq (200 mCi) every 8 wk for a total of 4 doses.
Solution for injection: 10 mCi/mL
Monitor for signs and symptoms of neuroendocrine hormonal crisis (flushing, diarrhea, hypotension, bronchoconstriction, other signs and symptoms of tumor-related hormonal release) periodically during. Administer IV somatostatin analogs, fluids, corticosteroids, and electrolytes as indicated.
Lab Test Considerations:
Verify negative pregnancy test before starting therapy.
Monitor CBC and platelet count during therapy. If Grade 2, 3, or 4 thrombocytopenia occurs, hold dose until complete or partial resolution (Grade 0 to 1). Resume Lutathera at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 2, 3 or 4 thrombocytopenia, administer Lutathera at 7.4 GBq (200 mCi) for next dose. Discontinue Lutathera permanently for ≥Grade 2 thrombocytopenia requiring treatment delay ≥16 wk. If Grade 2, 3, or 4 recurs, discontinue therapy permanently.
If Grade 3 or 4 anemia or neutropenia occurs, hold dose until complete or partial resolution (Grade 0, 1, or 2). Resume Lutathera at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 anemia or neutropenia, administer Lutathera at 7.4 GBq (200 mCi) for next dose. Permanently discontinue Lutathera for ≥Grade 3 anemia or neutropenia requiring treatment delay ≥16 wk. If Grade 3 or 4 recurs, discontinue therapy permanently.
Monitor serum creatinine and calculated CCr during therapy. If renal toxicity (CCr <40 mL/min; calculate using Cockcroft Gault with actual body weight, or 40% ↑ in baseline serum creatinine, or 40% ↓ in baseline CCr; calculate using Cockcroft Gault with actual body weight) occurs, hold dose until complete resolution or return to baseline. Resume Lutathera at 3.7 GBq (100 mCi) in patients with complete resolution. If reduced dose does not result in renal toxicity, administer Lutathera at 7.4 GBq (200 mCi) for next dose. Permanently discontinue Lutathera for renal toxicity requiring treatment delay ≥16 wk. If renal toxicity recurs, discontinue Lutathera permanently.
Monitor AST, ALT, bilirubin and serum albumin during therapy. If hepatotoxicity (bilirubinemia >3 × ULN (Grade 3 or 4), or hypoalbuminemia <30 g/L with ↓ prothrombin ratio <70%) occurs, hold dose until complete resolution or return to baseline. Resume Lutathera at 3.7 GBq (100 mCi) in patients with complete resolution or return to baseline. If reduced Lutathera dose does not result in hepatotoxicity, administer Lutathera at 7.4 GBq (200 mCi) for next dose. Permanently discontinue Lutathera for hepatotoxicity requiring treatment delay ≥16 wk. If hepatotoxicity recurs, permanently discontinue Lutathera.
Radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure. Use waterproof gloves and effective radiation shielding when handling drug. Used by or under control of health care professionals qualified by specific training and experience in safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by appropriate governmental agency authorized to license use of radiopharmaceuticals. Minimize radiation exposure to patients, medical personnel, and household contacts during and after therapy consistent with institutional good radiation safety practices, patient management procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection at home.
Discontinue long-acting somatostatin analogs (long-acting octreotide) least 4 wk before starting therapy. Administer short-acting octreotide as needed; discontinue at least 24 hr before starting therapy.
Administer long-acting octreotide 30 mg IM 4 to 24 hr after each dose during therapy. Do not administer long-acting octreotide within 4 wk of each subsequent dose. May give short-acting octreotide to manage symptoms during therapy, but hold for at least 24 hr before each dose.
Continue long-acting octreotide 30 mg IM every 4 wk after therapy is completed until disease progression or for up to 18 mos following after starting therapy.
Administer antiemetics before amino acid solution.
Start IV amino acid solution of L-lysine (18–25 g) and L-arginine (18–25 g) in 1–2 L volume 30 min before administering Lutathera. Use a 3-way valve to administer amino acids using same venous access as Lutathera or administer amino acids through separate venous access in patient's other arm. Continue infusion during and for at least 3 hr after Lutathera infusion. Do not decrease dose of amino acid solution if dose of Lutathera is reduced to decrease reabsorption of Lutathera through proximal tubules and decrease radiation dose to kidneys.
Use aseptic technique and radiation shielding when administering Lutathera. Use tongs when handling vial to minimize radiation exposure. Do not inject Lutathera directly into any other intravenous solution. Confirm amount of radioactivity of Lutathera in radiopharmaceutical vial with an appropriate dose calibrator before and after Lutathera administration. Solution is colorless to slightly yellow; do not administer solutions that are cloudy, discolored, or contain particulate matter. Dispose of any unused medicinal product or waste material in accordance with local and federal laws.
Intermittent Infusion: Insert a 2.5 cm, 20 gauge needle (short needle) into Lutathera vial and connect via a catheter to 500 mL 0.9% NaCl (to transport Lutathera during infusion). Ensure short needle does not touch Lutathera solution in vial and do not connect this short needle directly to patient. Do not allow 0.9% NaCl to flow into Lutathera vial before infusion and do not inject Lutathera directly into 0.9% NaCl. Insert a second, 9 cm, 18 gauge needle (long needle) into Lutathera vial ensuring that this long needle touches and is secured to bottom of Lutathera vial during entire infusion. Connect long needle to patient by an IV catheter that is prefilled with 0.9% NaCl and is used exclusively for Lutathera infusion.
Rate: Use a clamp or pump to regulate flow of 0.9% NaCl via short needle into Lutathera vial at a rate of 50–100 mL/hr for 5 to 10 min, then 200–300 mL/hr for additional 25 to 30 min (0.9% NaCl entering vial through short needle will carry Lutathera from vial to patient via catheter connected to long needle over a total duration of 30 to 40 min). During infusion, ensure level of solution in Lutathera vial remains constant. Disconnect vial from long needle line and clamp 0.9% NaCl once level of radioactivity is stable for at least 5 min. Follow infusion with an IV flush of 25 mL 0.9% NaCl.
Intermittent Infusion: Use when administering reduced dose of Lutathera after decreasing dose for an adverse reaction; gravity method may result in delivery of incorrect volume, if dose is not adjusted before administration. Insert 2.5 cm, 20 gauge needle (short venting needle) into Lutathera vial. Ensure short needle does not touch Lutathera solution in vial and do not connect short needle directly to patient or infusion pump. Insert second, 9 cm, 18 gauge needle (long needle) into Lutathera vial ensuring long needle touches and is secured to bottom of Lutathera vial during entire infusion. Connect long needle and 0.9% NaCl to 3way stopcock valve via appropriate tubing. Connect output of 3-way stopcock valve to tubing installed on input side of peristaltic infusion pump according to manufacturer's instruction. Purge line by opening 3-way stopcock valve and pumping Lutathera solution through tubing until it reaches exit of valve. Purge IV catheter connected to patient by opening 3-way stopcock valve to 0.9% NaCl and pumping 0.9% NaCl until it exits end of catheter tubing. Connect purged catheter to patient and set 3-way stopcock valve so Lutathera solution is in line with infusion pump.
Rate: Infuse one-half volume listed on Lutathera vial over a 30 min period (25 mL/hr). When correct volume of Lutathera delivered, stop infusion pump and change position of 3-way stopcock valve so that infusion pump is in line with 0.9% NaCl. Restart infusion pump and infuse an IV flush of 25 mL of 0.9% NaCl through catheter to patient.
Y-Site Incompatibility: Do not mix with or infuse with other drug or solutions.
Inform patient that Lutathera contributes to overall long-term radiation exposure. Long-term cumulative radiation exposure is associated with increased risk for cancer. Radiation can be detected in urine for up to 30 days after Lutathera administration. Provide instructions to patient for follow-up radiation protection at home to minimize radiation exposure household contacts.
Advise patient to urinate frequently during and after administration of Lutathera to decrease radiation dose to kidneys.
Advise patient to notify health care professional if signs and symptoms of infection (fever, chills, dizziness, shortness of breath, increased bleeding or bruising) and neuroendocrine hormonal crisis occur.
Caution patient to avoid crowds and persons with known infections. Instruct patient to use soft toothbrush and electric razor and to avoid falls. Patient should also be cautioned not to drink alcoholic beverages or to take products containing aspirin or NSAIDs; may precipitate GI hemorrhage.
Inform patient of risk for secondary cancers, including myelodysplastic syndrome and acute leukemia.
Rep: May cause fetal harm. Advise females of reproductive potential to use effective contraception during for 7 mo after last dose and to avoid breastfeeding during and for 2.5 mo after last dose. Advise males with female partners of reproductive potential to use effective contraception during and for 4 mo after last dose. May impair male and female fertility.
Emphasize importance of regular lab tests to monitor for side effects.
Improvement in progression-free survival.
lutetium lu 177 dotatate is a sample topic from the Davis's Drug Guide.
Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Complete Product Information.